2019
DOI: 10.1038/s41579-019-0293-3
|View full text |Cite
|
Sign up to set email alerts
|

Antibiotic development — economic, regulatory and societal challenges

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
195
0
2

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 295 publications
(197 citation statements)
references
References 8 publications
0
195
0
2
Order By: Relevance
“…The rate at which bacteria develops antibiotic resistance surpasses the discovery and development of combative new antibiotics. The lead reasons are due to the bureaucracy of regulations, scientific challenges, regulatory issues and inadequate profitability from the new products [6]. Evidently, it is important to explore innovative strategies to fight antimicrobial resistance infection.…”
Section: Introductionmentioning
confidence: 99%
“…The rate at which bacteria develops antibiotic resistance surpasses the discovery and development of combative new antibiotics. The lead reasons are due to the bureaucracy of regulations, scientific challenges, regulatory issues and inadequate profitability from the new products [6]. Evidently, it is important to explore innovative strategies to fight antimicrobial resistance infection.…”
Section: Introductionmentioning
confidence: 99%
“…The inappropriate use of antibiotics has selected for the global rise of antibiotic-resistant pathogens, rendering several existing antibiotics ineffective [1]. A potential strategy to overcome this rapid evolution of resistance is antibiotic combination therapy.…”
Section: Introductionmentioning
confidence: 99%
“…Emerging antimicrobial resistance of bacterial strains constitutes a worldwide major threat to mankind [ 1 ]. Lately, the race between the development of novel antibiotics and the progressive emergence of multi-drug resistant (MDR) bacterial strains has been highlighted, emphasising and contextualizing the role of “one health” [ 2 ]. This might be even further aggravated by the current wide use of antibiotics for the treatment of COVID-19 patients, in an attempt to prevent and treat bacterial superinfections.…”
Section: Introductionmentioning
confidence: 99%
“…During the last decades, an alarming rise in infections caused by carbapenem-resistant bacteria has been observed all around the world posing a global threat to human health [ 2 , 14 ]. In 2018, for instance, in some European countries such as Greece, Romania and Italy 63.9, 29.5 and 26.8% of clinical enterobacterial isolates have been tested resistant against carbapenems, respectively [ 14 ].…”
Section: Introductionmentioning
confidence: 99%